New Data to Be Presented at the ISTH 2020 Virtual Congress Demonstrating Octapharma’s Commitment to Patients With Bleeding Disorders
13.7.2020 14:37:00 EEST | Business Wire | Press release
Octapharma announced today that new research findings from its haematology portfolio will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress, taking place on 12–14 July 2020.
The NuProtect study (NCT01712438) investigated the immunogenicity, efficacy and safety of Nuwiq® (simoctocog alfa) in 108 previously untreated patients with haemophilia A. The final results of the study showed a cumulative incidence of high-titre anti-FVIII inhibitors of 17.6%. Patients who completed the NuProtect study were offered participation in a long-term extension study (NCT01992549). The results of the extension study will be presented for the first time at ISTH 2020.
In patients who develop inhibitors, immune tolerance induction (ITI) with repeated FVIII administration is the only proven approach to eradicate inhibitors. Three posters will be presented at ISTH 2020 reporting on the success of ITI with two of Octapharma’s FVIII products, octanate® and Nuwiq®.
The titles of the posters are provided below. All abstracts are available on the ISTH website.
Poster PB0999 Long-term immunogenicity, efficacy and safety of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect PUP study
Poster PB1001 Immune tolerance induction (ITI) with a single factor VIII/von Willebrand factor concentrate in haemophilia A patients with inhibitors - Update from the ObsITI Study
Poster PB1044 Immune tolerance induction with octanate® in patients with haemophilia A and inhibitors: An ongoing case series from a Malaysian centre
Poster PB1047 Immune tolerance induction with simoctocog alfa in patients with haemophilia A: An ongoing multicentre case series from the UK
Octapharma will be sponsoring two scientific symposia at ISTH 2020 on haemophilia A and von Willebrand disease (VWD). The haemophilia A symposium will include new clinical and real-world data on Nuwiq®, including final results from the NuProtect study and its long-term extension as well as experience with personalized prophylaxis in previously treated patients. New studies of ITI and the relevance of FVIII in managing joint and bone health will also be discussed. The VWD symposium will address the challenges of diagnosing VWD and particular issues facing women with VWD, as well as discussing the use of wilate® for prophylaxis and during surgery.
Both symposia will be held on Tuesday 14 July (8:45 am EDT and 10:15 am EDT) on the ISTH virtual congress platform and will be freely available to all healthcare professionals. The symposia will remain on the congress platform for 90 days and be available on the ISTH Academy website for one year.
“We are very pleased to share the positive data across our product portfolio addressing the needs of individuals with haemophilia and von Willebrand disease”, said Dr Larisa Belyanskaya, Head of IBU Haematology at Octapharma. Olaf Walter, Board Member at Octapharma, added that “the data cover the large spectrum of care required by patients with coagulation disorders, and demonstrate Octapharma’s commitment to improving patients’ lives at an individual level.”
About Octapharma
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. Octapharma employs more than 10,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Haematology, Immunotherapy, and Critical Care.
Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden, with a combined capacity of approximately 8 million litres of plasma per annum. In addition, Octapharma operates more than 140 plasma donation centres across Europe and the US. More information on www.octapharma.com
About Nuwiq®
Nuwiq® (simoctocog alfa) is a 4th generation recombinant factor VIII (rFVIII) protein, produced in a human cell line without chemical modification or fusion with any other protein1. It is cultured without additives of human or animal origin, is devoid of antigenic non-human protein epitopes and has a high affinity for von Willebrand factor1. Nuwiq® treatment has been assessed in seven completed clinical trials which included 201 previously treated patients (PTPs; 190 individuals) with severe haemophilia A, including 59 children1. Nuwiq® is available in 250 IU, 500 IU, 1000 IU, 2000 IU, 2500 IU, 3000 IU and 4000 IU presentations2. Nuwiq® is approved for use in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital FVIII deficiency) across all age groups2.
- Lissitchkov T et al. Ther Adv Hematol 2019; doi: 10.1177/2040620719858471.
- Nuwiq® Summary of Product Characteristics.
About wilate®
wilate® is a high-purity human von Willebrand factor/factor VIII (VWF/FVIII) concentrate, that undergoes two virus inactivation steps during its production.1 No albumin is added as a stabiliser1. The purification processes result in a 1:1 ratio of VWF to FVIII that is similar to normal plasma1. wilate® contains a VWF triplet structure and content of large high molecular weight multimers similar to normal human plasma1. wilate® is exclusively derived from large pools of human plasma collected in approved plasma donation centres2. wilate® is available in 500 IU and 1000 IU presentations. wilate® is indicated for the prevention and treatment of haemorrhage or surgical bleeding in von Willebrand disease (VWD), when desmopressin (DDAVP) alone is ineffective or contra-indicated, and for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency) 2.
- Stadler M et al. Biologicals 2006; 34:281-8.
- wilate® Summary of Product Characteristics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200713005330/en/
Contact information
Macarena Guillamon
corporatecommunications@octapharma.com
Phone: +41 055 451 21 21
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Launches First Advertising Campaign: “Unstoppable Energy”23.3.2026 12:30:00 EET | Press release
Today, Venture Global, Inc. (NYSE: VG) is launching its first national advertising campaign – “Unstoppable Energy”. The seven-figure, year-long campaign includes national and local broadcast television spots, as well as out-of-home, print, and digital ad placements. The company is proud to have Academy-Award winner Billy Bob Thornton as the campaign voiceover. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323692879/en/ “Venture Global is excited to unveil our very first national advertising campaign, featuring the accomplished Billy Bob Thornton as its voice,” said Venture Global CEO Mike Sabel. “The Unstoppable Energy campaign portrays the roll-up-your-sleeves tenacity and innovation that drives our company every day. We are proud to introduce the ethos and story of the Venture Global brand across the U.S. as we grow into one of the largest liquefied natural gas (LNG) exporters in the world.” About Venture Global Ventur
Venture Global and Vitol Announce New LNG Purchase Agreement23.3.2026 12:00:00 EET | Press release
Today, Venture Global, Inc. (NYSE: VG) and Vitol announced the execution of a new, binding agreement for the purchase of approximately 1.5 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for five years commencing in 2026, to be supplied from Venture Global’s portfolio. “Global demand for flexible, reliable U.S. LNG is rapidly growing, and Venture Global is proud to work with premier LNG trading companies like Vitol to provide this critical supply to the market,” said Venture Global CEO Mike Sabel. “Thanks to our innovative model, we have the ability to provide our customers with short, medium, and long-term LNG supply, and this agreement is another important step in diversifying the tenor of our LNG portfolio.” “Vitol is delighted to be working with Venture Global, a leading producer and supplier of LNG to world markets,” said Pablo Galante Escobar, Global Head of LNG at Vitol. “LNG is important to many economies worldwide. Through this transacti
RSA Launches ID Plus Sovereign Deployment: The Next Level of High Assurance Identity Security23.3.2026 12:00:00 EET | Press release
Today at RSAC Conference 2026, RSA, the security-first identity leader, announced the launch of RSA® ID Plus Sovereign Deployment, a groundbreaking evolution in high assurance identity solutions designed to meet the needs of organizations that must maintain constant availability, meet policy and data sovereignty laws, and defend themselves from advanced, persistent threats. RSA ID Plus Sovereign Deployment is the next evolution in RSA® ID Plus, the market’s most secure identity and access management (IAM) security platform featuring complete multi-factor authentication (MFA), SSO, and access capabilities. RSA ID Plus Sovereign Deployment features a new “deploy anywhere” capability that allows government agencies, financial services, critical infrastructure, and healthcare organizations to modernize their identity infrastructure while still maintaining the highest standards in security, availability, and regulatory compliance. Unlike other vendors that offer limited technology or reduce
Klarna Expands Its Partnership With H&M in Romania and Hungary23.3.2026 11:46:00 EET | Press release
Klarna, a global digital bank and provider of flexible payment solutions, and H&M, one of the world's largest fashion retailers, announce the expansion of their partnership in Romania and Hungary as a strategic step that strengthens the long-standing global collaboration between the two companies. Klarna is now available as a payment method for H&M customers in both markets, offering a smooth, more predictable checkout experience and payment options tailored to the different needs of shoppers. The integration of Klarna into H&M online stores is an important feature for customers, who will thus be able to access interest-free flexible payment options. More flexibility at checkout By integrating Klarna into the payment process, H&M customers shopping online in Romania and Hungary can benefit from a full range of deferred payment options, flexible solutions with no interest or fees if payment is made on time. Depending on eligibility, customers can choose between paying in full with Klarn
Recyclable Packaging and Responsible Water Management: Barilla’s Commitment to a More Sustainable Future23.3.2026 11:30:00 EET | Press release
With 99.8% of the packaging designed to be recyclable and a 45% increase in water recycled and reused in 2024 compared to 2022, Barilla continues to strengthen its commitment to the responsible management of resources. The company is reaffirming this commitment on the occasion of Global Recycling Day (March 18) and World Water Day (March 22), two moments that highlight the importance of increasingly sustainable production models – from efficient water management to the design of more circular packaging solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320294356/en/ Barilla Group's Rubbiano Plant (PR) WATER AS A STRATEGIC RESOURCE TO PROTECT A fundamental resource for pasta production and for the balance of ecosystems, water is a central element in Barilla’s management of its operations. The company works to progressively reduce water consumption in its production processes, promoting the responsible use of this re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom